I-01 Leon Aarons Population Pharmacokinetic Analysis of Ropivacaine and its Metabolite PPX from Pooled Data in Neonates, Infants and Children Wednesday 10:15-11:45 |
I-02 Mona Alameddine Population Pharmacokinetic Analysis and Effects of Raltegravir In HIV positive and Healthy Individuals Wednesday 10:15-11:45 |
I-03 Sarah Alghanem Development of a Tobramycin Dosage Adjustment Nomogram for Patients with Cystic Fibrosis Wednesday 10:15-11:45 |
I-04 Hesham Al-Sallami A semi-mechanistic model for estimating fat free mass in children Wednesday 10:15-11:45 |
I-05 Claire Ambery Modelling impact of dropout mechanisms in Chronic Obstructive Pulmonary Disease (COPD) Wednesday 10:15-11:45 |
I-06 Orna Amir Predictive Model for Identification of Responders/Non Responders in Metastatic Breast Cancer Patients Treated with Docetaxel Wednesday 10:15-11:45 |
I-07 Anders Kristoffersson Optimal design of in vitro time kill curve experiments for the evaluation of antibiotic effects. Wednesday 10:15-11:45 |
I-08 Claus Andersen Trial Sample Size Estimation and Study Design Assessment using Monte Carlo Sampling Wednesday 10:15-11:45 |
I-09 Jacqueline Anderson Comparative pharmacokinetics of dimethoate poisoning in the minipig and human Wednesday 10:15-11:45 |
I-10 Christian Bartels Population PK Model for Pooled Data of Different Oral Diclofenac Formulations Wednesday 10:15-11:45 |
I-11 Paul Baverel A novel covariate search method intended for PKPD models with nonparametric parameter distributions Wednesday 10:15-11:45 |
I-12 Caroline Bazzoli New features for population design evaluation and optimisation with R functions: PFIM Interface 3.1 and PFIM 3.2 Wednesday 10:15-11:45 |
I-13 Benoît Beck From the Experimental Model Settings to the Physical System for Interpretable Decision Making Wednesday 10:15-11:45 |
I-14 Francesco Bellanti Relevance of QT-RR correlations in the assessment of QTc-interval prolongation in clinical trial simulations Wednesday 10:15-11:45 |
I-15 Brendan Bender A semi-mechanistic population Pharmacokinetic-Pharmacodynamic (PKPD) model of thrombocytopenia characterizing the effect of trastuzumab-DM1 (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer Wednesday 10:15-11:45 |
I-16 Julie Bertrand Extensive Population Pharmacokinetic-Pharmacogenetic Study of Nevirapine in HIV-Infected Cambodian Patients Wednesday 10:15-11:45 |
I-17 Julie Bertrand Multiple SNP analysis with HyperLasso in Pharmacogenetic Studies using Nonlinear Mixed Effects Models Wednesday 10:15-11:45 |
I-18 Bruno Bieth Using a Systems Biology Approach to Explore Clinical Diversity and Investigate Mechanism of Drug Action: Example of the RAAS System in Hypertension Wednesday 10:15-11:45 |
I-19 Roberto Bizzotto Drug Effects on Sleep Data from a 28-Day Clinical Study in Insomniac Patients: Covariate Analysis Using a Multinomial Mixed-Effect Markov-Chain Model Wednesday 10:15-11:45 |
I-20 Marcus Björnsson Performance of non-linear mixed effects models with and without taking informative dropout into account Wednesday 10:15-11:45 |
I-21 Michael Block Mechanistic PBPK/PD modeling for prediction of study outcome of cancer therapies: Translating in-vitro information into valid in-vivo predictions Wednesday 10:15-11:45 |
I-22 Irina Bondareva Sequential Interacting Multiple Model (IMM) Bayesian Analysis of Carbamazepine and Valproate Repeated Therapeutic Drug Monitoring (TDM) Data from Epileptic Patients Wednesday 10:15-11:45 |
I-23 Guillaume Bonnefois A nonlinear mixed effect model to study albumin-mediated drug transport into endothelial cells in vitro. Wednesday 10:15-11:45 |
I-24 Stephan Borghorst Age Dependent Volume of Distribution of Pegylated Asparaginase (OncasparTM) in children and adults Wednesday 10:15-11:45 |
I-25 Massoud Boroujerdi A Negative feedback model for a mechanism based description of longitudinal observations: application for bone turnover biomarkers. Wednesday 10:15-11:45 |
I-26 Marion Bouillon-Pichault Modeling Pain score in clinical trials using a joint survival-longitudinal mixed model with a Beta distribution in presence of missing values not occurring at random. Wednesday 10:15-11:45 |
I-27 Marion Bouillon-Pichault Pharmacokinetic design optimization in children and estimation of maturation parameters: example of cytochrome P450 3A4 Wednesday 10:15-11:45 |
I-28 Christine Brandquist PK/PD Modeling of the Effect of Intravenous Doses of Anzemet® (dolasetron mesylate) and Its Metabolite (hydrodolasetron) on the QT Interval in Healthy Subjects Wednesday 10:15-11:45 |
I-29 Karl Brendel A comparison of MONOLIX, NONMEM 6 and NONMEM 7 based on a simulated PK example Wednesday 10:15-11:45 |
I-30 Margreke Brill Cefazolin pharmacokinetics in morbidly obese patients following a prophylactic dose during weight reducing surgery. Wednesday 10:15-11:45 |
I-31 Anne Brochot Specifying Models with Time Dependent Pharmacokinetic Parameters in NONMEM Wednesday 10:15-11:45 |
I-32 Jacob Brogren Separate vs. simultaneous analysis of co-primary endpoints in Alzheimer’s disease clinical trials Wednesday 10:15-11:45 |
I-33 Vincent Buchheit Efficient quality review for modeling input dataset Wednesday 10:15-11:45 |
I-34 Núria Buil Bruna The feasibility of model-based exposure calculations in preclinical toxicology Wednesday 10:15-11:45 |
I-35 Vicente G. Casabo Bioequivalence trials simulation to select the best analyte for acetylsalicylic acid Wednesday 10:15-11:45 |
I-36 Massimo Cella Implementation of Pharmacokinetic Bridging for Drug Combinations in Children Wednesday 10:15-11:45 |
I-37 Anne Chain Can First-Time-In-Human Trials Replace Thorough QT Studies? Wednesday 10:15-11:45 |
I-38 Pascal Chanu A dose selection rationale based on hemodynamics for sildenafil in pediatric patients with pulmonary arterial hypertension (PAH) Wednesday 10:15-11:45 |
I-39 Georgia Charkoftaki Pharmacokinetics of doripenem in cerebrospinal fluid Wednesday 10:15-11:45 |
I-41 Marylore Chenel Developing an In Vitro – In Vivo Correlation Model Using a Population Approach in NONMEM Wednesday 10:15-11:45 |
I-42 Marylore Chenel BSA-adjusted dose? An old method to fight old bias Wednesday 10:15-11:45 |
I-43 S. Y. Amy Cheung Structural identifiability of parallel pharmacokinetic experiments as constrained systems Wednesday 10:15-11:45 |
I-44 Jason Chittenden Evaluation of the Lindstrom-Bates FOCE Algorithm with Simulated Pharmacokinetic Datasets Wednesday 10:15-11:45 |
I-45 Steve Choy Application of an integrated glucose-insulin model to investigate the effects of glibenclamide and its active metabolites on postprandial glucose and insulin concentrations in healthy volunteers Wednesday 10:15-11:45 |
I-46 Christine Xu Population Pharmacokinetics (PPK) and Pharmacokinetic-Pharmacodynamic (PK/PD) of Vicriviroc in Treatment Naive HIV Wednesday 10:15-11:45 |
I-47 Jae Yong Chung Modelling of Atorvastatin Pharmacokinetics in relation to SLCO1B1 genotype and Simulations for Bioequivalence Study Wednesday 10:15-11:45 |
I-48 Karina Blei Evaluation of a PBPK Model for Preterm Neonates by Predicting Paracetamol Pharmacokinetics Wednesday 10:15-11:45 |
I-49 Adriaan Cleton Population Pharmacokinetics of a Monoclonal Antibody Tanezumab in Chronic Pelvic Pain Conditions Wednesday 10:15-11:45 |
I-50 Emmanuelle Comets SAEMIX, an R version of the SAEM algorithm Wednesday 10:15-11:45 |
I-51 Emmanuelle Comets Prediction discrepancies (pd) for evaluation of models with data under limit of quantification Wednesday 10:15-11:45 |
I-52 Emmanuelle Comets A comparison of bootstrap approaches for estimating standard errors of parameters in linear mixed effects models Wednesday 10:15-11:45 |
I-53 Carolyn Coulter Utilising prior literature population models to inform clinical practice - a dosing regimen for immediate N-acetyl cysteine treatment of paracetamol overdose Wednesday 10:15-11:45 |
I-54 Alexander Danis Set-valued methods for estimation of parameters in population models Wednesday 10:15-11:45 |
I-55 Roosmarijn De Cock Maturation of GFR in preterm and term neonates reflected by clearance of different antibiotics Wednesday 10:15-11:45 |
I-56 Elizabeth de Lange Mechanism-based PK-PD model of remoxipride with rat-to-human extrapolation: characterizing remoxipride target site PK and systems homeostatic feedback Wednesday 10:15-11:45 |
I-57 Willem de Winter Dynamics of a Two-Receptor Binding Model: How Affinities and Capacities Translate into Long- and Short-Term Behaviour and Physiological Corollaries Wednesday 10:15-11:45 |
I-58 Maud Delattre Pharmacokinetics and stochastic differential equations : model and methodology. Wednesday 10:15-11:45 |
I-59 Ivan Demin Longitudinal model-based meta-analysis in rheumatoid arthritis: an application towards model based drug development Wednesday 10:15-11:45 |
I-60 Paolo Denti Population PK of Isoniazid in South African Adults. Wednesday 10:15-11:45 |
I-61 Vincenzo Luca Di Iorio Application of Stochastic Differential Equations to Disease Progression in a Neuropathic Pain Model in Rats Wednesday 10:15-11:45 |
I-62 Kristin Dickschen Pharmacogenomics of Tamoxifen In Female Patients: A PBPK Model-based Investigation Including The Three Main Metabolites Wednesday 10:15-11:45 |
I-63 Jeroen Diepstraten Pharmacodynamics of nadroparin using anti-Xa levels in morbidly obese patients upon subcutaneous administration of 5700 IU Wednesday 10:15-11:45 |
I-64 Aris Dokoumetzidis Numerical solution of nonlinear fractional compartmental systems Wednesday 10:15-11:45 |
I-65 Aris Dokoumetzidis Multiple dosing for linear fractional pharmacokinetic systems Wednesday 10:15-11:45 |